Leerink Partnrs Issues Pessimistic Outlook for IDXX Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) – Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for IDEXX Laboratories in a research note issued on Thursday, May 1st. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $3.03 for the quarter, down from their previous estimate of $3.04. The consensus estimate for IDEXX Laboratories’ current full-year earnings is $11.93 per share. Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $12.04 EPS.

Other equities research analysts have also issued reports about the stock. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Finally, Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $524.75.

IDEXX Laboratories Stock Down 0.3 %

IDXX stock opened at $473.71 on Monday. IDEXX Laboratories has a one year low of $356.14 and a one year high of $548.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm’s fifty day moving average is $420.26 and its 200 day moving average is $428.49. The firm has a market cap of $38.39 billion, a PE ratio of 44.40, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business had revenue of $998.43 million for the quarter, compared to analysts’ expectations of $998.25 million. During the same quarter last year, the company earned $2.71 EPS. The business’s revenue was up 3.6% on a year-over-year basis.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in shares of IDEXX Laboratories by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock worth $948,279,000 after purchasing an additional 37,734 shares during the last quarter. Bamco Inc. NY boosted its stake in IDEXX Laboratories by 4.3% during the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company’s stock worth $829,163,000 after buying an additional 82,264 shares during the period. Franklin Resources Inc. increased its position in shares of IDEXX Laboratories by 2.5% during the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after acquiring an additional 34,305 shares during the last quarter. Invesco Ltd. raised its stake in shares of IDEXX Laboratories by 6.8% in the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock valued at $479,999,000 after acquiring an additional 74,324 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of IDEXX Laboratories by 58.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock worth $472,865,000 after acquiring an additional 414,802 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.